Evidence map›Paper›PMID 26375767›Full record

Trial reportJournal of child and adolescent psychopharmacology2015

Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.

Ditte L Vernal, Sandeep Kapoor, Aseel Al-Jadiri, Eva M Sheridan, Yehonathan Borenstein, Charles Mormando, Lisa David, Sukhbir Singh, Andrew J Seidman, Maren Carbon and 5 more

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of child and adolescent psychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Ditte L Vernal1 Research Unit for Child and Adolescent Psychiatry, Psychiatric Hospital, Aalborg University Hospital , Denmark .
Sandeep Kapoor2 The Zucker Hillside Hospital , Psychiatry Research, North Shore-Long Island Jewish Health System, Glen Oaks, New York.
Aseel Al-Jadiri2 The Zucker Hillside Hospital , Psychiatry Research, North Shore-Long Island Jewish Health System, Glen Oaks, New York.
Eva M Sheridan2 The Zucker Hillside Hospital , Psychiatry Research, North Shore-Long Island Jewish Health System, Glen Oaks, New York.
Yehonathan Borenstein2 The Zucker Hillside Hospital , Psychiatry Research, North Shore-Long Island Jewish Health System, Glen Oaks, New York.
Charles Mormando2 The Zucker Hillside Hospital , Psychiatry Research, North Shore-Long Island Jewish Health System, Glen Oaks, New York.
Lisa David2 The Zucker Hillside Hospital , Psychiatry Research, North Shore-Long Island Jewish Health System, Glen Oaks, New York.
Sukhbir Singh2 The Zucker Hillside Hospital , Psychiatry Research, North Shore-Long Island Jewish Health System, Glen Oaks, New York.
Andrew J Seidman2 The Zucker Hillside Hospital , Psychiatry Research, North Shore-Long Island Jewish Health System, Glen Oaks, New York.
Maren Carbon2 The Zucker Hillside Hospital , Psychiatry Research, North Shore-Long Island Jewish Health System, Glen Oaks, New York.
Miriam Gerstenberg3 University Clinics of Child and Adolescent Psychiatry, University of Zurich , Switzerland .
Ema Saito2 The Zucker Hillside Hospital , Psychiatry Research, North Shore-Long Island Jewish Health System, Glen Oaks, New York.
John M Kane2 The Zucker Hillside Hospital , Psychiatry Research, North Shore-Long Island Jewish Health System, Glen Oaks, New York.
Hans-Christoph Steinhausen1 Research Unit for Child and Adolescent Psychiatry, Psychiatric Hospital, Aalborg University Hospital , Denmark .
Christoph U Correll2 The Zucker Hillside Hospital , Psychiatry Research, North Shore-Long Island Jewish Health System, Glen Oaks, New York.
Zucker Hillside Hospital · USAlbert Einstein College of Medicine · USAalborg University Hospital · DKUniversity of Basel · CHUniversity of Zurich · CH

Funding

HYBRIDIZATION MEASUREMENT OF PROOPIOMELANOCORTIN NRNAF31MH009059 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KELSEY, JEFFREY E · 1985 to 1985
–
NIMH NIH HHS P30MH09059
6 · The paper itself

Abstract

objectivesThe purpose of this study was to assess differences in the outcomes of youth with schizophrenia-spectrum disorders (SCZ-S) and psychotic disorder not otherwise specified (PsyNOS) during early antipsychotic treatment.

methodsThe study was a prospective, naturalistic, inception cohort study of youth ≤19 years old with SCZ-S (schizophrenia, schizoaffective disorder, schizophreniform disorder) or PsyNOS (PsyNOS, brief psychotic disorder) and ≤24 months of lifetime antipsychotic treatment receiving clinician's choice antipsychotic treatment. Baseline demographic, illness and treatment variables, and effectiveness outcomes were compared at 12 weeks last-observation-carried-forward across SCZ-S and PsyNOS patients, adjusting for significantly different baseline variables.

resultsAltogether, 130 youth with SCZ-S (n=42) or PsyNOS (n=88), mostly antipsychotic naïve (76.9%), were prescribed risperidone (47.7%), olanzapine (19.2%), aripiprazole (14.6%), quetiapine (11.5%), or ziprasidone (6.9%). Compared with those with PsyNOS, SCZ-S youth were older (16.4±2.1 vs. 14.8±3.2, p=0.0040), and less likely to be Caucasian (19.1% vs. 42.5%, p=0.009). At baseline, SCZ-S patients had significantly higher Clinical Global Impressions-Severity (CGI-S) scores (6.0±0.9 vs. 5.5±0.8, p=0.0018) and lower Children's Global Assessment Scale (CGAS) scores (29.6±9.2 vs. 36.1±8.9, p=0.0002) and were more likely to be in the severely ill CGAS group (i.e., CGAS≤40). SCZ-S and PsyNOS patients did not differ regarding all-cause discontinuation (40.5 vs. 40.3%. p=0.49), discontinuation because of adverse effects (12.2% vs. 12.4%, p=0.97), or nonadherence (29.3% vs. 30.9%, p=0.88), but somewhat more SCZ-S patients discontinued treatment for inefficacy (19.5% vs. 7.4%, p=0.063). CGI-S and CGAS scores improved significantly in both diagnostic groups (p=0.0001, each). Adjusting for baseline differences, PsyNOS patients experienced significantly better CGI-I improvement (CGI-I) scores (p=0.012) and more frequently reached higher categorical CGAS group status (p=0.021) than SCZ-S patients.

conclusionsBoth youth with SCZ-S and those with PsyNOS experienced significant improvements with clinician's choice antipsychotic treatment. However, treatment discontinuation was common within 12 weeks, with greater inefficacy-related discontinuation in the SCZ-S group, whereas CGI-I and CGAS score-based improvements were greater in the PsyNOS group.

Indexed as

AdolescentAntipsychotic AgentsBenzodiazepinesFemaleHumansMaleOlanzapineProspective StudiesPsychiatric Status Rating ScalesPsychotic DisordersRisperidoneSchizophreniaTreatment OutcomeAntipsychotic AgentsBenzodiazepinesOlanzapineRisperidone

Identifiers

PMID26375767
PMCPMC4696429
OpenAlexW1939154885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.